<DOC>
	<DOCNO>NCT01612988</DOCNO>
	<brief_summary>ICLL01 The BOMP trial : Phase II study salvage treatment Bendamustine , Ofatumumab MethylPrednisolone ( BOMP ) relapse B-cell chronic lymphocytic leukemia ( B-CLL ) . A study GOELAMS / GCFLLC-MW intergroup</brief_summary>
	<brief_title>Treatment With Bendamustine , Ofatumumab MethylPrednisolone Relapsed B-CLL</brief_title>
	<detailed_description>Available data suggest combination bendamustine , ofatumumab high dose steroid ( BOMP regimen ) appear meaningful likely induce high response rate patient relapse CLL , include relapse modern 1st line immuno-chemotherapy combination fludarabine-refractory . The BOMP trial address complete response rate main objective . The result bendamustine rituximab CLL2M trial serve comparator BOMP trial . Among secondary objective , extensive study p53 pathway ( deletion 17p , TP53 mutational status p53 function ) perform impact response survival analyze .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Age &gt; 18 year &lt; 80 year 2 . Diagnosis CLL accord IWCLL 2008 criterion fulfil Matutes Moreau score ≥ 4 3 . Relapsed refractory CLL stage A , B C active disease require therapy accord IWCLL 2008 criterion 4 . Relapse refractory 1 3 previous line include least one line fludarabine 5 . ECOG Performance status general condition . ECOG Performance status ≤ 2 Fit Patients : CIRS ( Cumulative Illness Rating Scale ) less equal 6 Life expectancy 3 month Note : Patients fulfil inclusion criterion present follow feature also include : patient rate 17p deletion FISH patient candidate allogeneic transplantation , provide patient planned receive full BOMP treatment program final restaging assessment patient fludarabine refractory disease patient prior diagnostic CLL , time previous line ( ) treatment relapse without hyperlymphocytosis ( lymphocytes &lt; 5000/mm3 ) ( lymphocytic lymphoma ) prior monoclonal antibody ( alemtuzumab rituximab ) exposure provide washout period 3 month start BOMP treatment . 1 . Untreated CLL 2 . ECOG Performance Status &gt; 2 3 . Serious accompany disorder impair organ function indicate : Abnormal renal function creatinine clearance &lt; 40 ml/min calculate accord formula Cockcroft Gault Absolute neutrophils &lt; 1,000/mm3 , platelet &lt; 75000/mm3 ( unless due malignant B Cell involvement bone marrow and/or spleen enlargement ) Liver test : total bilirubin &gt; 1.5 time UNL ( unless due CLL involvement liver know history Gilbert 's disease ) , transaminase ( ALAT , ASAT ) and/or alkaline phosphatase &gt; 2.5 time UNL ( unless due CLL involvement liver ) Clinically significant cardiac disease include unstable angina , acute myocardial infarction within six month prior study enrollment , congestive heart failure ( NYHA IIIIV ) , arrhythmia unless controlled therapy , exception extra systole minor conduction abnormality . Severe chronic obstructive pulmonary disease hypoxemia pulmonary diffusion capacity &lt; 40 % Uncontrolled diabetes mellitus , Uncontrolled hypertension History significant cerebrovascular disease past 6 month ongoing event active symptom sequelae Significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease opinion investigator may represent risk patient . 4 . CIRS ( Cumulative Illness Rating Scale ) &gt; 6 5 . Clinically significant autoimmune anemia [ i.e . drop hemogolobin level relate hemolytic autoimmune process attest follow marker : elevate indirect bilirubin , elevate LDH , low haptoglobin level , high reticulocyte count along positive direct antierythrocyte test ( Coombs direct test ) ] 6 . Transformation aggressive Bcell malignancy ( e.g . diffuse large cell lymphoma , Hodgkin 's lymphoma , prolymphocytic leukaemia ) 7 . Prior treatment antiCD20 monoclonal antibody alemtuzumab within 3 month prior start therapy . 8 . Prior autologous transplantation allogeneic transplantation 9 . Prior treatment bendamustine and/or ofatumumab 10 . Active second malignancy currently require treatment ( except basal cell carcinoma , situ cervix carcinoma incidental prostate carcinoma ) . Subjects free malignancy least 5 year eligible . 11 . Known HIVpositivity 12 . Positive serology hepatitis B ( HB ) ( except post vaccinale pattern ) and/or hepatitis C. Positive serology HB define positive test HBs antigen antiHBc antibody ( regardless HBsAb status ) . 13 . Current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , stable chronic liver disease per investigator assessment ) 14 . Simultaneous participation another study protocol 15 . Known hypersensitivity medication use specially humanized monoclonal antibody study drug 16 . Chronic current bacterial , viral fungal infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis 17 . Any coexist medical psychological condition would preclude participation require study procedures 18 . Patient mental deficiency prevent proper understanding requirement treatment . 19 . Pregnant breastfeed woman . 20 . Person major lawcontrol 21 . Lactating woman 22 . Fertile male female patient wish use effective method contraception , 12 month final treatment use purpose study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Méthylprednisolone</keyword>
</DOC>